

AlzeCure gives live streamed update on Painless Platform

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that it will give a live streamed update focusing on its project platform Painless on May 11 at 09:00 CEST. The presentation will be followed by a Q&A session and discussion led by Anders Hedlund, analyst at Redeye.

Martin Jönsson, CEO, together with Märta Segerdahl, CMO, Pontus Forsell, Head of Discovery & Research, and Johan Sandin, CSO, will present the Painless platform and the progress made in the projects, with recent positive clinical results from the phase Ib trial with ACD440, which is focused on neuropathic pain, and advancements made in the preclinical project TrkA-NAM for osteoarthritic pain and other severe pain disorders. These projects complement AlzeCure's broad Alzheimer's portfolio.

Watch the livestream on May 11 at 09:00 CEST via:

<https://www.redeye.se/events/809997/strategy-update-alzecure-pharma>

The presentation will be held in English and will be available on the company's website afterwards at:

<https://www.alzecurepharma.se/sv/presentationer-och-intervjuer/>.

For more information, please contact

Martin Jönsson, CEO

Tel: +46 707 86 94 43

martin.jonsson@alzecurepharma.com

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain – indications for which currently available treatment is extremely limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure® aims to pursue its own projects through preclinical research and development to early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.

FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se.

Attachments

AlzeCure gives live streamed update on Painless Platform